These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17031407)

  • 1. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer.
    Eggington S; Tappenden P; Pandor A; Paisley S; Saunders M; Seymour M; Sutcliffe P; Chilcott J
    Br J Cancer; 2006 Nov; 95(9):1195-201. PubMed ID: 17031407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
    Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
    Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
    Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
    Cassidy J; Douillard JY; Twelves C; McKendrick JJ; Scheithauer W; Bustová I; Johnston PG; Lesniewski-Kmak K; Jelic S; Fountzilas G; Coxon F; Díaz-Rubio E; Maughan TS; Malzyner A; Bertetto O; Beham A; Figer A; Dufour P; Patel KK; Cowell W; Garrison LP
    Br J Cancer; 2006 Apr; 94(8):1122-9. PubMed ID: 16622438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
    Haller DG; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Gilberg F; Rittweger K; Schmoll HJ
    J Clin Oncol; 2011 Apr; 29(11):1465-71. PubMed ID: 21383294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
    Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
    Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
    Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
    Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
    Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers.
    Soni A; Aspinall SL; Zhao X; Good CB; Cunningham FE; Chatta G; Passero V; Smith KJ
    Oncol Res; 2014; 22(5-6):311-9. PubMed ID: 26629943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of adjuvant chemotherapy in colon cancer.
    Labianca R; Milesi L; Mosconi S; Pessi MA; Beretta GD; Quadri A
    Surg Oncol; 2007 Dec; 16 Suppl 1():S93-6. PubMed ID: 18257148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
    Chu E; Schulman KL; McKenna EF; Cartwright T
    Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.
    Lin JK; Tan EC; Yang MC
    Health Qual Life Outcomes; 2015 May; 13():61. PubMed ID: 25986478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
    Glen H; Cassidy J
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
    Wen F; Yao K; Du ZD; He XF; Zhang PF; Tang RL; Li Q
    World J Gastroenterol; 2014 Dec; 20(47):17976-84. PubMed ID: 25548497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
    Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
    J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
    Carrato A; Gallego-Plazas J; Guillén-Ponce C
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.